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Abstract
Eradication of the smallpox virus through extensive global vaccination efforts has resulted in one
of the most important breakthroughs in medical history, saving countless lives from the severe
morbidity and mortality that is associated with this disease. Although smallpox is now extinct in
nature, laboratory stocks of this virus still remain and the subject of smallpox vaccination has gained
renewed attention due to the potential risk that smallpox may be used as a biological weapon by
terrorists or rogue states. Despite having the longest history of any modern vaccine, there is still
much to be learned about smallpox vaccination and the correlates of protection remain to be
formally defined. This Commentary will discuss the strengths and weaknesses of traditional
smallpox vaccination in comparison with immunization using modified vaccinia virus Ankura (MVA),
a non-replicating virus with a strong safety record but weakened immunogenicity.
Introduction
Smallpox (Variola major) is a virus that no longer exists in
the wild, but during its reign it caused 20–30% mortality
in previously unvaccinated individuals and often left sur-
vivors with deeply pitted scars for life [1]. The last case of
smallpox in the U.S. occurred in 1949 and the last case of
naturally occurring smallpox in the world occurred in
Somalia in 1977. Smallpox has no known animal reser-
voir, so in the absence of any more natural cases of human
smallpox being recorded after 1977, the virus was consid-
ered fully eradicated in 1980 [1]. Despite extinction in
nature, smallpox virus stocks still reside in secure loca-
tions within the U.S. and Russia but it is impossible to
know if other undeclared stocks of smallpox remain in
other countries [2]. Moreover, in the age of genetic engi-
neering it is possible that more virulent strains of small-
pox or other potentially dangerous orthopoxviruses could
be developed and unleashed in an effort of bioterrorism.
Although the potential for developing a pathogen more
lethal than wild smallpox is theoretically possible [2,3] it
would by no means be a simple task to undertake and the
outcome would likewise be uncertain [4,5]. Nevertheless,
smallpox is considered a potential risk to national security
and efforts are underway to prepare the United States and
several other countries for a deliberate release of smallpox
as a biological weapon.
The first line of defense against smallpox is vaccination.
Smallpox vaccination is highly effective at protecting
against lethal infection and even if only partial protective
immunity is attained, this often still results in survival and
decreased viral spread to others (Chapter 4, pages 189–90
of [1]). The smallpox vaccine was discovered by Edward
Jenner, who was the first to prove that infection by cow-
pox resulted in protective cross-reactive immunity against
smallpox [6]. Dr. Jenner not only demonstrated that cow-
pox could induce protective immunity, but in answer to
critics of his day who argued that this form of immunity
would only be short-lived, he demonstrated full protec-
tion against smallpox in several individuals at 25, 27, 31,
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38, and even 53 years after cowpox infection [6,7]. It is not
a coincidence that such long-term time points were exam-
ined. As Dr. Jenner noted, "I have purposely selected several
cases in which the disease [i.e. cowpox] had appeared at a very
distant period previous to the experiments made with variolous
matter, to show that the change produced in the constitution is
not affected by time." [6].
Following the elegant studies initiated by Edward Jenner,
the world was eventually freed of the scourge of smallpox
following a massive global eradication campaign [1] and
although hugely successful, there were still many ques-
tions that were left unanswered. These questions represent
the topics of this commentary. For instance, by then end
of the 1960's it was realized that smallpox vaccination was
the cause of a substantial number of adverse events and
resulted in a lethal infection in approximately one out of
one million people who received this live viral vaccine. In
Germany, an extremely safe attenuated strain of vaccinia,
known as modified vaccinia virus, Ankura (MVA) was
developed [8,9], but it was only used as primary vaccina-
tion followed by traditional smallpox vaccination. More-
over, its efficacy against smallpox was never directly tested
due to the eradication of smallpox shortly thereafter and
the question remains as to whether it would induce full or
only partial immunity when faced against fully virulent
smallpox. Although the virology, pathology, and epide-
miology of smallpox are well described [1], there is a rel-
ative dearth of information regarding the immunology of
smallpox and smallpox vaccination. Most importantly,
there is currently no consensus on the immunological cor-
relates of protection, making it difficult to implement
rationale vaccine design when it not established which
immunological benchmarks are necessary for full or even
partial protection. Recent quantitative analysis of the cel-
lular and humoral immune response following smallpox
vaccination, coupled with historical evidence of protective
immunity, are beginning to shed light on this important
subject.
Discussion
The question of safety following smallpox vaccination
The current smallpox vaccine was prepared prior to 1982
under standards that today, would be unlikely to be
approved by the FDA. To produce the vaccine, the torso of
bovine calves were shaved, and their skin scarified
(scratched) with an inoculum containing vaccinia virus.
After the infection has reached a point in which a great
deal of exudate was observed, the purulent lymph mate-
rial was scraped from the infected cow, clarified, and
lyophilized in the presence of antibiotics. The inoculum is
later reconstituted with diluent containing 0.25% phenol
to further decrease bacterial contamination (<200 viable
bacterial/mL after reconstitution; see Dryvax package
insert). Unlike most other vaccines that are administered
by subcutaneous or intramuscular injection, vaccinia
virus replicates poorly under these conditions and opti-
mal vaccination occurs by scarification of the virus inocu-
lum onto the skin surface [10]. Viral replication on the
skin surface typically results in a vesicular or pustular
lesion that is described as a "take" which later crusts over
and sloughs off, leaving behind a small scar. Since the
time of Edward Jenner, the presence of a vesicular or pus-
tular lesion has remained the gold-standard measurement
of successful vaccination.
The success of smallpox vaccination does not come with-
out unwanted consequences. The most common side
effects of smallpox vaccination are fever and other flu-like
symptoms. More serious adverse events include inadvert-
ent inoculation (529 cases/106 doses), generalized vac-
cinia (242 cases/106 doses), eczema vaccinatum (39 cases/
106  doses), vaccinia necrosum (1.5 cases/106  doses),
encephalitis (12 cases/106 doses), or death (~1 death/106
doses) [11]. The mortality rate is highest for infants that
are <1 year of age (5 deaths/106 doses) whereas the mor-
tality rate for older children and adolescents aged 1–4 or
5–19 is approximately 0.5 deaths/106  doses (see also
[12,13] and Dryvax package insert). It is rare for adults to
die after smallpox vaccination; of 68 deaths attributed to
smallpox vaccination over a 9-year period of evaluation,
only 8/68 (12%) of cases occurred in adults. Five of the
eight adults were over the age of 60 and 4/8 of the lethal
cases occurred in adults who were diagnosed with termi-
nal cancer at the time of vaccination [11].
Myopericarditis is a recently identified adverse event that
occurs at a rate of ~124 cases/106 smallpox vaccinations
[14,15]. In 2003, there were three fatal heart attacks that
were temporally related to smallpox vaccination and this
triggered critical evaluation of any vaccine-related cardiac
events thereafter. It was later realized that all three heart
attack victims (age 55, 55, and 57) had pre-existing risk
factors for cardiac disease including hypertension, hyperl-
ipidemia, and smoking. At autopsy, none of the three
heart attack victims showed signs of myo/pericarditis but
the deaths were instead linked directly to ischemic events
[16]. A retrospective study analyzing the number of car-
diac deaths among approximately 80,000 death certifi-
cates issued near the time of a massive smallpox
vaccination effort in New York City in 1947 has also
brought new insight into the dangers of smallpox vaccine-
induced myocarditis[16]. Following an imported case of
smallpox, about 6.4 million people of all ages were vacci-
nated in a one-month period. Analysis of the frequency of
cardiac deaths before, during, and after the vaccination
campaign failed to show a statistical increase in these
events. Moreover, analysis of 64 recently identified cases
of myocarditis in the U.S. military smallpox vaccination
program found that approximately 80% of patientsMedical Immunology 2005, 4:2 http://www.medimmunol.com/content/4/1/2
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reported no long term sequelae and 100% of patients
demonstrated objective normalization of echocardiogra-
phy, electrocardiography, laboratory testing, graded exer-
cise testing, and functional status [15].
To overcome some of the problems associated with the
current calf lymph smallpox vaccine (Dryvax), an
improved tissue culture-derived vaccine has been recently
developed [17]. Unlike Dryvax, this new vaccine (desig-
nated ACAM1000) is produced under sterile GMP condi-
tions, so bacterial contamination is avoided. Also, unlike
Dryvax which contains a heterologous mixture of virus
variants with some differing in their neurovirulence
[17,18], ACAM1000 is clonally derived (triple plaque-
purified) and tested extensively for low neurovirulence in
animal studies. Thus, it is hopeful that ACAM1000 vac-
cine will have reduced risk of encephalitis, one of the
major risk factors following smallpox vaccination. It
remains to be seen whether or not myopericarditis or
other potentially serious adverse events will be affected by
the use of this new vaccine.
Both Dryvax and ACAM1000 represent replication-com-
petent smallpox vaccines and since these vaccines are
based on the use of live viruses, there is always an inherent
risk of severe adverse events or death (albeit rare) in vac-
cinees that have unknown or undisclosed immunodefi-
ciencies at the time of vaccination. To overcome the
hazards of replicating viruses, a highly attenuated strain of
vaccinia, designated Modified Vaccinia virus Ankara
(MVA) was developed by growing the virus for >500 pas-
sages on chicken embryo fibroblasts (CEF) and following
the loss of about 15% of its parental genome, it no longer
was capable of replicating in most mammalian cells,
including human cells [19]. Other strains of non-replicat-
ing orthopoxviruses have also been developed, including
NYVAC, which was derived from vaccinia virus following
a deletion of 18 genes – including those encoding viru-
lence factors and human host range replication, and
ALVAC, an attenuated viral vector that is based on canary-
pox, an avipoxvirus that grows only in avian species. In
one study, recombinant NYVAC and recombinant ALVAC
expressing JEV proteins were found to be well tolerated
but more reactogenic than the commercially available for-
malin-inactivated JEV vaccine [20]. Of these attenuated
poxvirus vaccine strains, MVA is the one with the most
extensive history of safety in humans. Beginning in 1968,
>100,000 people in Germany were vaccinated with MVA
(followed by traditional smallpox vaccination) and
although it was well tolerated, MVA was not used alone
and since there were no smallpox outbreaks at that time,
its efficacy in the face of an actual smallpox outbreak has
not been tested. With an excellent safety profile in
humans and in animal models of immunodeficiency,
recombinant MVA expressing candidate immunogens
from a variety of infectious agents (e.g. HIV, HPV, and
malaria) or tumor antigens (e.g. melanoma) have now
reached Phase I and Phase II clinical trials [21,22]. How-
ever, the role of MVA in the future of smallpox vaccination
has yet to be decided and will likely be determined by the
outcome of clinical trials that directly compare the immu-
nogenicity of MVA to either Dryvax or ACAM1000, two
vaccines that are likely to provide the required high levels
of protective immunity that will be necessary in the event
of an accidental or deliberate smallpox outbreak.
Quantitative analysis of vaccine efficacy
Edward Jenner developed the first test for vaccine efficacy
when he immunized subjects with cowpox and then later
challenged them with smallpox by inoculation. If a sub-
ject showed no secondary smallpox lesions indicative of
systemic spread, then the individual was believed to have
protective immunity. He noted that cowpox-vaccinated
individuals who developed a pox-like lesion at the vacci-
nation site were fully protected against smallpox chal-
lenge. To this day, most studies still use the identification
of a "take" (vesicular or pustular lesion) as evidence of
successful vaccination. However, there are rare cases of
revaccinated subjects who present with vesicle formation
after smallpox vaccination, but show no detectably
boosted cellular or humoral immunity [23] and M.K.
Slifka, unpublished results). For this reason, it is impor-
tant that pre- and post-vaccination serum antibody and
peripheral T cell responses be monitored in individuals
who plan to work with virulent orthopoxviruses or who
would be expected to enter a hot zone in the case of a
smallpox outbreak.
Quantitative immunology is beginning to gain acceptance
as a measurement of vaccine efficacy, although the Jenne-
rian vesicle at the site of smallpox vaccination still
remains the primary endpoint of successful vaccination in
most studies [17,23-25]. One of the reasons why quanti-
tative immunology is more important now than ever
before is that with some vaccines such as MVA, there is no
vesicle formed due to the route of immunization – so
unless immunological measurements are made, then vac-
cine immunogenicity cannot be determined or compared.
Humoral immunity following smallpox vaccination was
measured in the 1960's and 1970's by means of neutraliz-
ing assays (primarily against the IMV form of vaccinia or
smallpox) and today, humoral immune responses are
quantitated by analysis of neutralizing activity against
IMV or EEV forms of vaccinia or by the use of ELISA assays
using whole-virus lysate and/or individual vaccinia IMV
or EEV proteins. Moreover, the vaccinia-specific memory
B cell response has also been recently studied [26] provid-
ing the first direct quantitation of this memory cell subset.
Quantitation of the antiviral T cell response mounted
after smallpox vaccination was not an option during theMedical Immunology 2005, 4:2 http://www.medimmunol.com/content/4/1/2
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smallpox era because the tools and technology were not
available for analysis of cellular immunity. In contrast,
today there are now several sophisticated techniques that
can be used to monitor antiviral T cell responses directly
ex vivo including vaccinia-specific IFNγ  ELISPOT assays
[17,23,26-28], intracellular cytokine staining analysis
(ICCS) [29-33], or peptide/MHC Class I tetramer staining
[28,30]. Each of these techniques has high sensitivity and
high specificity and each has both advantages and disad-
vantages. For instance, the IFNγ  ELISPOT assay provides a
highly sensitive calculation of IFNγ -producing cells, but
one drawback is that it only allows detection of one
cytokine at a time and the phenotype of the IFNγ -produc-
ing subset (CD4, CD8 or possibly NK cells) must be deter-
mined by purifying each population independently prior
to the assay. The advantage of ICCS is that antiviral T cells
can be quantitated based on the production of more than
one cytokine and the phenotype of the responding lym-
phocyte subset is directly determined by flow cytometry.
The main disadvantage of ICCS is that a relatively large
number of cells are required in order to detect rare popu-
lations of virus-specific T cells. The advantage of using
peptide/MHC tetramers is that CD8+ T cells can be quan-
titated regardless of their cytokine profiles, but the main
disadvantages with this approach include the lack of iden-
tified CD4+ T cell/MHC Class II epitopes, the requirement
for knowledge of the MHC haplotype of the subject, and
the inability to measure the total antiviral T cell response,
which may be directed against any number of immuno-
dominant and subdominant peptide epitopes.
Direct quantitation of the antiviral immune response
induced by smallpox vaccination has been critical for sev-
eral recent advances in orthopoxvirus immunobiology –
especially since smallpox has been eradicated and other
human orthopoxvirus outbreaks are too small and spo-
radic (e.g. cowpox [34,35] or monkeypox [36,37]) to be
feasible for field studies of protective efficacy. For exam-
ple, Weltzin et al. [17] not only compared the neutralizing
titers induced by Dryvax vs. ACAM1000 vaccines, but also
compared vaccinia-specific T cell responses by IFNγ  ELIS-
POT as well as by cytolytic T cell assays and proliferation
assays that, although less quantitative than the ELISPOT
assay, are nevertheless important for analysis of antiviral
T cell functions. These techniques allowed the investiga-
tors to demonstrate non-inferiority of the new tissue cul-
ture-derived smallpox vaccine compared to the Dryvax
vaccine that is currently in use.
Another study by Earl et al. [38], used quantitative immu-
nology to compare vaccine efficacy of Dryvax, MVA fol-
lowed by a Dryvax booster, and MVA followed by an MVA
booster in a cynomolgus monkey (Macaca fascicularis)
model of monkeypox infection. Using ELISA assays and
neutralizing assays to measure vaccinia-specific antibody
responses, and ICCS to measure antiviral T cell responses,
the authors showed that antiviral immunity appeared
similar between these three groups. Likewise, each of
these groups were protected against lethal monkeypox
challenge, although primates that only received MVA plus
an MVA booster showed partial protection with 6/6 ani-
mals presenting with 1–36 monkeypox lesions (com-
pared to >500 monkeypox lesions in the unvaccinated
controls). This indicates that two MVA vaccinations are
required to induce partial immunity whereas MVA fol-
lowed by Dryvax immunization or a single Dryvax immu-
nization each provides full immunity. The protective
efficacy of a single dose of MVA is unknown, but based on
the results of the Earl et al. study [38] wherein two doses
were required to elicit partial immunity, it appears likely
that a single dose of MVA would be of only low protective
value in the face of a virulent orthopoxvirus infection.
This is not surprising since MVA, NYVAC, and ALVAC (all
replication-deficient vaccines), typically require booster
doses to be administered in order to elicit optimal
immune responses. Moreover, several prime-boost strate-
gies (including DNA vaccination followed by MVA
booster) are being tested in order to overcome the low
immunogenicity of MVA alone [21]. This is different from
most replicating viruses [39] including vaccinia, which
require only one immunization (or infection) to induce
optimal and often lifelong immunity [5,26,32,40].
Approximately half of the U.S. population has been vacci-
nated against smallpox and continue to maintain pre-
existing antiviral immunity [26,32] and this may have an
impact on the efficacy of MVA vaccination. For instance,
studies involving the closely related, non-replicating
NYVAC strain have found that pre-existing immunity sig-
nificantly effected the outcome of vaccination [20]. In this
particular study, immunization with recombinant NYVAC
expressing JEV proteins failed to induce protective anti-
bodies in 0/5 vaccinia pre-immune individuals and
although 5/5 vaccinia-naive subjects seroconverted after
NYVAC-JEV immunization, the resulting neutralizing tit-
ers were substantially lower than that observed in subjects
who received the standard formalin-inactivated JEV vac-
cine [20]. Oddly, the authors noted that both the NYVAC-
JEV and the ALVAC-JEV vaccines (2 doses administered 28
days apart) failed to induce a detectable anti-vaccinia neu-
tralizing response.
It is difficult to speculate the efficacy of MVA vaccination
of humans as a method of protection against smallpox. It
is possible that booster doses of MVA would provide
strong enough immunity to at least protect against lethal
smallpox, similar to its ability to protect primates from
lethal monkeypox [38]. On the other hand, clinical trials
could indicate that MVA vaccination alone may be too
inconsistent or only induce low levels of immunity that
would be considered inferior to live smallpox vaccinationMedical Immunology 2005, 4:2 http://www.medimmunol.com/content/4/1/2
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with calf-lymph or tissue culture-derived vaccine prepara-
tions. Unlike live smallpox vaccination, which can be
used as an effective post-exposure treatment against the
lethal consequences of smallpox [1,5], it is unlikely that
the low immunogenicity of MVA would be capable of ful-
filling this role. Moreover, in the event of a smallpox out-
break there would not be enough time to administer two
or more doses of MVA if people were at a high risk of
exposure. Under these circumstances, use of live viral vac-
cines would be critical for ring vaccination or mass vacci-
nation scenarios. This is not to say that MVA would not
have a potential role in biodefense strategies. For instance,
in a pre-event scenario, one could foresee the use of MVA
followed by vaccination with a live viral vaccine such as
Dryvax or its equivalent. Under these circumstances, MVA
would likely induce partial immunity that would reduce
the adverse events that are associated with traditional
smallpox vaccination. Moreover, MVA is the vaccine of
choice in immunocompromised individuals with sup-
pressed immune systems (cancer patients, organ-trans-
plant patients, AIDS patients, etc.) who would otherwise
be contra-indicated for administration of the live viral
vaccines. More studies will be needed to determine the
immunogenicity and protective efficacy of MVA and other
related non-replicating vaccines in terms of their potential
to counter a smallpox outbreak.
The need for formal definition of protective immunity and 
the correlates of immunity
There is more than one definition of protective immunity
against smallpox. There is protection against infection,
protection against disease, and protection against death.
Of these, one might argue that protection against lethal
infection is the ultimate definition of protective immu-
nity. However, protection against infection and protec-
tion against disease not only reduce the morbidity of an
outbreak, but these high levels of protective immunity are
also associated with reduced virus spread to others (Chap-
ter 4, pages 189–90 of [1]). Protection against infection is
the most rare level of protective immunity since this
requires that an infection be blocked at the point of entry.
A meta-analysis of 10 epidemiological studies on small-
pox noted that on average, the virus only infected ~4% of
previously vaccinated household contacts (Chapter 4,
pages 189–90 of [1]). However, these results were based
on whether or not the vaccinated contacts showed disease
symptoms and did not necessarily prove that they were
never infected per se. Further analysis indicated that
approximately 10% of previously vaccinated household
contacts of smallpox patients were actually infected with
smallpox as demonstrated by isolation of infectious virus
from pharyngeal mucosa, but only 4/34 (12%) of these
subjects developed the clinical symptoms of smallpox
[41]. Moreover, another study showed that about 50% of
previously vaccinated, disease-free contacts demonstrated
serological results indicative of a recent orthopoxvirus
infection [42]. This suggests that most instances of "pro-
tection against infection" may not be complete protec-
tion. Instead, many of the individuals thought to have had
protection against infection may have actually been
infected with smallpox but didn't know it because they
were clinically asymptomatic. Similar to these historical
studies, during the U.S. monkeypox outbreak in 2003 [37]
we have identified three previously unreported cases of
monkeypox in subjects who had received smallpox vacci-
nation many years earlier and were unaware that they had
become infected with monkeypox because they were
spared any recognizable disease symptoms (M.K. Slifka,
unpublished data).
A major issue in the smallpox field is that there is no con-
sensus on what is exactly required for protective immunity
against this disease. In the age of quantitative immunol-
ogy, we are beginning to find clues that might help answer
this age-old question. In a study of >300 subjects, the lev-
els of vaccinia-specific serum antibody and antiviral T cell
responses were determined from 30 days to up to 75 years
after smallpox vaccination [32]. Antiviral antibody
responses were maintained essentially for life, whereas
antiviral CD4+ and CD8+ T cell responses declined with a
half-life of approximately 8–15 years, with CD4+ T cell
memory being more stable than CD8+ T cell responses.
Similar duration of antibody production was demon-
strated by other recent studies as well as older literature
[24,26,40]. Moreover, the gradual loss of T cell memory
was also confirmed [26], as was the differential loss of
CD8+ T cell memory over CD4+ T cell memory [33]. Based
on historical analysis of vaccine-mediated protection
against lethal smallpox (dating back to the age of Edward
Jenner), indicates that protective immunity is often life-
long [40]. One might argue that if protective immunity
against smallpox had an absolute requirement for antivi-
ral CD4+ or CD8+ T cells, then protective immunity would
not be life-long but would instead be more likely to
decline at the same rates as T cell memory. This suggests
that in humans, humoral immunity might play a more
important role in protection against lethal infection than
cellular immunity [5,40]. Smallpox disease symptoms
become more pronounced with increased time since vac-
cination [43], and it likely that the combination of intact
cellular and humoral immunity together provide the most
robust antiviral immunity. Recent vaccinia studies in mice
using either antibodies to deplete T cell subsets or mouse
strains that are genetically deficient in CD4+ T cells or
CD8+ T cells (or both) have indicated that, as long as there
is strong humoral immunity against vaccinia, T cell mem-
ory is dispensable for protective immunity [44-46]. This
result corresponds well with other studies in which pro-
tection against vaccinia or smallpox has been clearly dem-
onstrated by the adoptive transfer of immune serum inMedical Immunology 2005, 4:2 http://www.medimmunol.com/content/4/1/2
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humans or by transfer of monoclonal neutralizing anti-
bodies in animal models [5,40]. On the other hand, adop-
tive transfer of virus-specific T cells and experiments in
mice that are genetically deficient in B cells, also indicate
that in the absence of pre-existing antibody responses,
memory T cells can play an important role in protection.
This indicates that cellular and humoral immunity have
overlapping roles in protective immunity and one may
compensate for a deficiency in the other.
Based on the overlapping roles for T cell and B cell mem-
ory on protective immunity, is there any chance that a
consensus can be reached in regard to defining an immu-
nological correlate of immunity? One way to address this
issue is to examine historical studies in which an immu-
nological correlate was identified. In this regard, there are
two independent studies in which investigators showed
that subjects with vaccinia-specific neutralizing antibody
titers of >1:20 [47] or ≥  1:32 [48] were fully protected
against smallpox. The latter study was the largest of the
two and showed that 3/15 (20%) of subjects with titers
below 1:32 contracted smallpox whereas 0/127 (<1%) of
subjects with antibody titers of ≥  1:32 contracted the dis-
ease. The only caveat to these studies is that the subjects
also received post-exposure vaccination at the same time
that serum samples were drawn, so the full protection
afforded to the subjects with high pre-existing neutraliz-
ing titers may have been due to their high antibody titers,
or the combination of strong pre-existing antibody titers
in the context of post-exposure vaccination. A neutralizing
titer of 1:32 is equivalent to a vaccinia ELISA titer of 944
Elisa Units (EU) or approximately 4 International Units
(IU) of the WHO/NIBSC International Smallpox Serum
Standard [32]. Interestingly, about 50% of subjects vacci-
nated in the distant past maintain neutralizing titers of
1:32 or greater for life and this coincidentally is the same
proportion of vaccinated smallpox contacts who demon-
strated fully protective immunity when exposed to small-
pox-infected family members [42]. This leads one to
speculate that 4 IU may constitute a protective level of
serological immunity against smallpox. This is a testable
hypothesis and to determine if this is a correlate of protec-
tion, it will be important to perform adoptive transfer of
VIG or its equivalent into non-human primates (resulting
in antiviral serum antibody levels of approximately 1:32)
and determine if they are protected against a lethal
orthopoxvirus infection, such as following monkeypox
challenge. This experiment would prove or disprove the
hypothesis that a serological correlate of protective immu-
nity exists and may lay the foundation for future vaccine
design. Of note, the protective level of yellow fever immu-
nity (log10 ≥  0.7 neutralizing titer) was also established in
non-human primates by simply vaccinating groups of ani-
mals with different doses of the yellow fever vaccine,
quantitating vaccine-induced antibody levels, and then
challenging them with a lethal dose of yellow fever virus
[49]. This serological correlate of protection (which
ignores the role of vaccine-induced T cell responses) has
been established as the benchmark of protective yellow
fever virus-specific immunity for over 30 years and dem-
onstrates the potential for using animal models to corre-
late protective immunity in humans.
Conclusion
Traditional smallpox vaccination has lead to the global
eradication of smallpox but continues to be used today in
an effort to thwart the potential use of smallpox as a bio-
logical weapon. Since this vaccine employs the use of a
live virus, there is an inherent risk of adverse events,
although these are generally quite rare. New generation
smallpox vaccine candidates include MVA and other non-
replicating poxviruses and although they demonstrate a
high degree of safety, their immunogenicity appears to be
substantially lower than traditional smallpox vaccination
with live vaccinia virus. The role of MVA and traditional
smallpox vaccination (or a combination thereof) in future
vaccination campaigns has yet to be determined. How-
ever, developing a consensus on the definition of what is
required for protective immunity and defining an immu-
nological correlate of immunity would aid in the evalua-
tion of current and future vaccine approaches.
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